NCT07101601 is a Phase 1 clinical trial of DM5167 in Advanced Breast Cancer, sponsored by DIGMBIO.

Who is sponsoring NCT07101601?

NCT07101601 is sponsored by DIGMBIO.

What drugs are being tested in NCT07101601?

Interventions in NCT07101601: DM5167.

What condition does NCT07101601 study?

NCT07101601 studies Advanced Breast Cancer.

Is NCT07101601 still recruiting?

NCT07101601 is currently recruiting now. Last updated 3 August 2025.

Last reviewed 2025-08-03 · How we verify

NCT07101601

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of DM5167 in Patients With Advanced Solid Tumors

Recruiting now Phase 1 Last updated 3 August 2025

What this trial tests

Phase 1 trial testing DM5167 in Advanced Breast Cancer in 58 participants. Currently enrolling.

Timeline

24 October 2024

Primary endpoint
30 October 2026

31 January 2027

Quick facts

Lead sponsor	DIGMBIO
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	58
Start date	24 October 2024
Primary completion	30 October 2026
Estimated completion	31 January 2027
Sites	4 locations across South Korea

Drugs / interventions tested

DM5167 — full drug profile →

Conditions studied

Advanced Breast Cancer — all drugs for Advanced Breast Cancer →

Sponsor

DIGMBIO — full company profile →

Who can join

19 and older, any sex, with Advanced Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme. This results in less haematological toxicity and a high level of safety. The aim of the study is to assess the safety and tolerability of DM5167 in patients with advanced solid tumors not respond to other treatments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Advanced Breast Cancer

Currently open trials in the same condition.

NCT07408089 — Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer · Phase 1 · recruiting
NCT07318805 — A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
NCT07259226 — Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers · Phase 2 · recruiting
NCT06982521 — Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PI · Phase 3 · recruiting
NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07101601 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by DIGMBIO
Last refreshed: 3 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07101601.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing